



Contribution ID: 85

Type: Oral

## Possibilities of production and isolation of the promising Auger emitter $^{195m}\text{Pt}$ for potential application in radiotheranostics

Alexander S. Madumarov, Gospodin A. Bozhikov, Nikolay V. Aksenov

JINR, Dubna, al.madumarov@jinr.ru

Recently radionuclides emitting Auger and conversion electrons have gained a lot of attention in radiotherapy. If their decay is accompanied by soft  $\text{X}$ -radiation those radionuclides can potentially be used for theranostics which implies combination of therapy and diagnostics in a single medical procedure with the same radioisotope and is currently considered extremely advantageous strategy for cancer treatment. Such radionuclides are known with the examples like  $^{67}\text{Ga}$ ,  $^{117m}\text{Sn}$ ,  $^{123}\text{I}$ ,  $^{86}\text{Y}$  ( $^{90}\text{Y}$ ),  $^{64}\text{Cu}$  ( $^{67}\text{Cu}$ ),  $^{124}\text{I}$  ( $^{131}\text{I}$ ),  $^{195m}\text{Pt}$  and some of them are already successfully used in clinical practice.

$^{195m}\text{Pt}$  emits one of the highest numbers of Auger electrons and  $\gamma$ -radiation appropriate for detection which makes it an ideal candidate for theranostics. Introduction of  $^{195m}\text{Pt}$  into cisplatin would enhance therapeutic effect at a lower cytotoxicity [1]. However, there is so far no suitable method to produce  $^{195m}\text{Pt}$  with a sufficient yield and specific activity high enough to meet the requirements for carrying out radionuclide therapy. In this work we investigate two perspective ways to produce the radioisotope of interest and characterise nuclear reactions involved with respect to their cross sections.

The first method takes advantage of photonuclear production by irradiation of natural Pt with bremsstrahlung at the microtron MT-25 (JINR, FLNR) according to the reactions  $^{196}\text{Pt}(\gamma, n)^{195m}\text{Pt}$  and  $^{195}\text{Pt}(\gamma, \gamma')^{195m}\text{Pt}$ . Photonuclear method is a powerful and effective tool to produce isomeric radioisotopes with high yield particularly relevant for nuclear medicine. The results of the flux-weighted average cross section  $\langle\sigma\rangle$  determination for the reactions mentioned will be presented. It is important to add here that we have increased the initial specific activity by one order of magnitude with the respective chemical yield of 80% using a target mixture of cisplatin and cryptomelane with latter serving as a recoil nuclei catcher and further separation of these two target components.

The second approach aimed to boost the specific activity of the radioisotope studied is indirect production of no-carrier-added  $^{195m}\text{Pt}$  by double neutron capture reaction of enriched  $^{193}\text{Ir}$  at a reactor by the nuclear process  $^{193}\text{Ir}(n, \gamma)^{194}\text{Ir}(n, \gamma)^{195m}\text{Ir} \beta^- \rightarrow ^{195m}\text{Pt}$ . This approach was proposed by the American researchers but was not characterised numerically [2]. Our work is a detailed study of the process mentioned by an activation technique at IBR-2 reactor (JINR, FLNP) and contains the first results of the unknown cross sections determination for the reaction  $^{194}\text{Ir}(n, \gamma)^{195m}\text{Ir}$ . We have found the reaction  $^{194}\text{Ir}(n, \gamma)^{195m}\text{Ir}$  resonance neutrons cross section to be 2900 b substantially prevailing the corresponding value for thermal neutrons with the specific activity of  $^{195m}\text{Pt}$  after 17 days of irradiation of 20 mg of  $^{193}\text{Ir}$  at IBR-2 amounting to 38.7 MBq/(mg Pt), making a reactor with a higher flux of fast neutrons to be a preferential condition for  $^{195m}\text{Pt}$  production [3].

### References

1. Zeevaart JR, Wagener J, Marjanovic-Painter B, Sathekge M, Soni N, Zinn C et al. J Labelled Comp Radiopharm 2013;56:495–503. <https://doi.org/10.1002/jlcr.3091>.
2. Knapp, F.F.R.; Mirzadeh, S.; Beets A.L.; Du, M. J Radioanal Nucl Chem 2005, 263, 503–9.
3. A.S. Madumarov, N.V. Aksenov, G.A. Bozhikov et al. Nuclear Medicine and Biology, Volumes 134–135, 2024, 108928, ISSN 0969-8051, <https://doi.org/10.1016/j.nucmedbio.2024.108928>.

### Notes

**Primary author:** Dr MADUMAROV, Alexander (JINR)

**Presenter:** Dr MADUMAROV, Alexander (JINR)